Michael C. Wilson

Array ( [id] => 18615706 [patent_doc_number] => 20230282445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => METHOD OF NUCLEAR REPROGRAMMING [patent_app_type] => utility [patent_app_number] => 18/146644 [patent_app_country] => US [patent_app_date] => 2022-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12372 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18146644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18610962 [patent_doc_number] => 20230277692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => HUMANIZED RODENTS FOR TESTING THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 18/089267 [patent_app_country] => US [patent_app_date] => 2022-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18089267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18466084 [patent_doc_number] => 20230200363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => TRANSGENIC FLUORESCENT ORNAMENTAL AMPHIBIANS [patent_app_type] => utility [patent_app_number] => 18/085601 [patent_app_country] => US [patent_app_date] => 2022-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18085601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18469256 [patent_doc_number] => 20230203540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED TARGETED INTEGRATION OF TRANSGENES INTO MAMMALIAN LIVER CELLS [patent_app_type] => utility [patent_app_number] => 18/085420 [patent_app_country] => US [patent_app_date] => 2022-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18085420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18707617 [patent_doc_number] => 20230330194 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => METHODS OF CYTOTOXIC GENE THERAPY TO TREAT TUMORS [patent_app_type] => utility [patent_app_number] => 17/993717 [patent_app_country] => US [patent_app_date] => 2022-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17993717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597581 [patent_doc_number] => 20230272377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1) [patent_app_type] => utility [patent_app_number] => 17/985974 [patent_app_country] => US [patent_app_date] => 2022-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17985974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709555 [patent_doc_number] => 20230332175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => TRANSGENIC RABBIT WITH COMMON LIGHT CHAIN [patent_app_type] => utility [patent_app_number] => 18/052113 [patent_app_country] => US [patent_app_date] => 2022-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522147 [patent_doc_number] => 20230232795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => NON-HUMAN ANIMALS HAVING HUMANIZED FC-GAMMA RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/967510 [patent_app_country] => US [patent_app_date] => 2022-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17967510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18198449 [patent_doc_number] => 20230051968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => PLAKOPHILLIN-2 GENE THERAPY METHODS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/938568 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18223970 [patent_doc_number] => 20230062964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => MODIFIED MICE THAT PRODUCE HEAVY CHAIN ONLY ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/823506 [patent_app_country] => US [patent_app_date] => 2022-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692932 [patent_doc_number] => 20230323290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS [patent_app_type] => utility [patent_app_number] => 17/884069 [patent_app_country] => US [patent_app_date] => 2022-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17884069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18209806 [patent_doc_number] => 20230056066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => PLAKOPHILLIN-2 GENE THERAPY METHODS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/882314 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17882314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18180919 [patent_doc_number] => 20230041648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => PLAKOPHILLIN-2 GENE THERAPY METHODS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/882395 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17882395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18179557 [patent_doc_number] => 20230040286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => METHODS OF PRODUCING HUMAN FOREGUT ENDODERM CELLS EXPRESSING PDX1 FROM HUMAN DEFINITIVE ENDODERM [patent_app_type] => utility [patent_app_number] => 17/814791 [patent_app_country] => US [patent_app_date] => 2022-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55001 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18055489 [patent_doc_number] => 20220386575 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => GENETICALLY MODIFIED T CELL RECEPTOR MICE [patent_app_type] => utility [patent_app_number] => 17/814388 [patent_app_country] => US [patent_app_date] => 2022-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23236 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18345531 [patent_doc_number] => 20230133641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => VIABLE GALACTOSYLTRANSFERASE KNOCK-OUT SHEEP AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 17/812342 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19439355 [patent_doc_number] => 12089576 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Nucleic acids comprising a modified rodent activin a receptor type 1 (Acvr1) gene [patent_app_type] => utility [patent_app_number] => 17/811089 [patent_app_country] => US [patent_app_date] => 2022-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12238 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19808333 [patent_doc_number] => 12239692 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Adeno-associated virus factor VIII vectors [patent_app_type] => utility [patent_app_number] => 17/854286 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 52 [patent_no_of_words] => 15089 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17854286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19736666 [patent_doc_number] => 12213466 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Process for using CRISPR to transfect primordial germ cells in avians [patent_app_type] => utility [patent_app_number] => 17/809219 [patent_app_country] => US [patent_app_date] => 2022-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 45 [patent_no_of_words] => 13949 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17809219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18272157 [patent_doc_number] => 20230093399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => METHODS FOR GENERATING PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS [patent_app_type] => utility [patent_app_number] => 17/825112 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17825112 [rel_patent_id] =>[rel_patent_doc_number] =>)